IGF1R and breast carcinoma: The present study was aimed at: (1) evaluating the efficacy of IGF1R inhibition as monotherapy in comparison to combination treatment with chemotherapy in breast cancer cells; (2) assessing the potential synergism achieved by combination therapy; and (3) characterizing this combined approach from a proteomic/bioinformatics perspective.